Aminoglycosides Market Size, Analysis, Share & Forecast 2031

Report Description

The global aminoglycosides market size is estimated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising incidence of bacterial infections caused by gram-positive and gram-negative bacteria along with growing usage of drugs in the treatment of different bacterial infections in humans as well as animals.

Get Free Sample Report

Aminoglycoside is a medical and bacteriologic categorization for antibacterial drugs that inhibit protein synthesis in gram-negative bacteria. It contains an amino-adjusted glycoside component of the molecule (sugar). Aminoglycosides, β -lactams, tetracyclines, sulfonamides, quinolones, fluoroquinolones, macrolides, and phenicols are the eight primary classes. These medications are used to treat a variety of bacterial infections in both people and animals. The use of these class of medicines to combat infection resistance and as antibacterials is fueling the market expansion. According to the World Health Organization (WHO) report, there were 368 million persons with tuberculosis-related hearing loss were recorded in 2013. South East Asia, Asia Pacific, and Sub-Saharan Africa had the highest rate of hearing loss in both children and adults over 65 years of age. Furthermore, according to the National Institutes of Health (NIH), total funding for infectious diseases in the United States was roughly USD 6.37 billion in 2019, up from USD 6.02 billion in 2018 and USD 6.02 billion in 2017.

However, prioritizing immunity enhancers in the current COVID-19 pandemic is critical aspect in fighting against the infection disease. For example, according to a study published in the Medical Hypotheses Journal in June 2020 by Nehru Sai Suresh Chalichem et al., aminoglycosides were discovered to exhibit defense-mediated antiviral action, which increases immunity.

Market Trends, Drivers, Restraints, and Opportunities

• Introduction of digital health agenda by WHO and European Respiratory Society (ERS) for eradication of tuberculosis is expected to boost the market growth.
• Presence of Global Drug Facility (GDF) and UNITAID is expected to increase drug demand in the market globally. It is anticipated to upsurge the market growth in the coming years.
• Growing incidence of animal disease outbreaks leading to high utilization of antibiotics is likely to fuel the market growth.
• Reduction in prescription rate of aminoglycoside antibiotics due to side effects associated with usage of these drugs is a restraining factor affecting the market growth.
• Strict regulatory policies regarding the approval of drugs for the usage of certain aminoglycoside is estimated to hamper the market in coming years.
• Existence of yearly procurement requirement by GDF and STOP TB Foundation is a great opportunity for the market expansion.

Scope of the Report

The report on the global aminoglycosides market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Gentamicin segment is expected to grow at a rapid pace

Based on drugs, the global aminoglycosides market is segmented into tobramycin, neomycin, amikacin, gentamicin, paromomycin, kanamycin, streptomycin, and others. The gentamicin segment is expected to grow at a rapid pace during the forecast period. Gentamicin is widely used to treat serious bacterial infections such as infections of the lungs, blood, bones, skin, joints, urinary system, and meningitis. For serious bacterial infections, gentamicin is most preferable drug by experts.

Get Free Sample Report

As per the report of 2020 by WHO, the need for wide research on SARS-CoV-2 has immensely increased, the diagnosis of corona virus infections relies heavily on the careful and germ-free collection of specimens. Furthermore, a customized viral transport medium (VTM) is required to collect specimens and preserved the virus from environmental degradation while providing an adequate, long-term transportation system. In addition, a 0.8 mL Gentamicin sulphate solution is widely used to avoid contamination.

Respiratory segment is projected to expand at a considerable CAGR

On the basis of applications, the market is segregated as UTI & pelvic diseases, neonatal sepsis, skin, veterinary, respiratory, and others. The respiratory segment is projected to expand at a considerable CAGR during the forecast period owing to the higher incidence of tuberculosis in the developing regions. Furthermore, rising incidence of multi-drug resistant tuberculosis and increasing financing for international organizations that provide subsidized tuberculosis treatment are expected to boost the segment growth during the forecast period.

However, the veterinary segment is anticipated to grow considerably in the coming years. The growth of the segment is attributed to the reduction in usage to avoid adverse effects and the development of resistance in food produced by animals treated with aminoglycosides.

Injectable administration segment is estimated to gain a large revenue share

Based on modes of administration, the global aminoglycosides market is divided into parenteral, intra-mammary, topical, and oral. The injectable administration segment is estimated to gain a large revenue share during the forecast period due to the increased human medical usage as they deliver ideal mode of action mechanism through intravenous or intramuscular route for disease treatment.
On the other hand, aminoglycoside antibiotics have effective activity against E. coli, proteus, pseudomonas, shigella, salmonella, enterobacter, and serratia in animals, they are widely used in veterinary medicine in the form of feed to increase drug bioavailability. The poultry and pig industries accounted for the majority of sales of in-feed and in-water aminoglycoside products.

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period. The regional market growth is attributed to the rising cases of bacterial infections, increasing demand for early-phase diagnosis & treatment of infectious diseases, and growing support from the government in the prevention of infection. According to the Centers for Disease Control and Prevention (CDC) data from 2018, the number of deaths caused by pneumoconiosis was approximately 1632 between the age of 15 and above in the US. Thus, the demand for aminoglycosides in the prevention of infectious diseases is projected to propel the regional market growth. However, the market of Asia Pacific is expected to register a high CAGR during the forecast period owing to presence of many key players in emerging economies such as India, Japan, and China.

Get Free Sample Report